Skip to content

Prediction of DNA Methylation in Hypertensive Patients for the Incidence and Prognosis of LVH

Prediction of DNA Methylation in Hypertensive Patients for the Incidence and Prognosis of LVH

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075404
Enrollment
Unknown
Registered
2023-09-04
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Hypertension with LVH:None
Hypertension validation group:None
Hypertension with LVH validation group:None

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Control group inclusion criteria for hypertension: ? Patients diagnosed with primary hypertension without left ventricular hypertrophy. The diagnostic criteria for primary hypertension are as follows: average 24-hour blood pressure =130/80; clinic blood pressure =140/90; isolated systolic hypertension with systolic blood pressure =140 and diastolic blood pressure <90 mm Hg (1 mm Hg = 0.133 kPa); ? Age range of 35-75 years; ? Signed informed consent form. Inclusion criteria for hypertension with left ventricular hypertrophy group: ? Patients meeting the diagnostic criteria for primary hypertension with left ventricular hypertrophy. The diagnostic criteria for primary hypertension are as follows: average 24-hour blood pressure =130/80; clinic blood pressure =140/90; isolated systolic hypertension with systolic blood pressure =140 and diastolic blood pressure <90 mm Hg (1 mm Hg = 0.133 kPa); the diagnostic criteria for left ventricular hypertrophy are as follows: echocardiography shows left ventricular mass index (LVMI) =115 (males) or =95 g/m2 (females); ? Age range of 35-75 years; ? Signed informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: ? Patients with secondary hypertension; ? Patients with primary or other secondary cardiomyopathies; ? Patients with malignant tumors, thyroid dysfunction, or severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
DNA methylation;receiver operating characteristic curve, ROC;

Countries

China

Contacts

Public ContactYuqi Liu

chinese PLA General Hospital

ametuofo980869@163.com+86 150 1146 1841

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026